Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Toshima Parris

Researcher

Toshima Parris
Researcher
toshima.parris@oncology.gu.se

Postal Address: Sahlgrenska universitetssjukhuset, 41345 Göteborg
Visiting Address: Blå stråket 2 su/jubileusklin , 41345 Göteborg


Department of Oncology at Institute of Clinical Sciences (More Information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
0313428503
Visiting Address: Blå stråket 2 SU/Jubileusklin , 413 45 Göteborg

About Toshima Parris

Research area:
Translational research on the development of novel treatment options for breast- and ovarian cancer.

Research environment
Toshima Parris works in a multidisciplinary research group comprised of several biologists (molecular biologist/geneticist), specialists in oncology, pathology, surgery, and radiation physics, as well as, one PhD student and a Masters student. Her research is conducted at the Department of Oncology and Sahlgrenska Center for Cancer Research.

Background
The main objective of this proposal is to discover new treatment options for triple-negative breast cancer (TNBC) that prevent recurrence and metastasis. In 2018, approximately 2.1 million new breast cancer cases were reported worldwide. TNBC accounts for about 15-20% of these cases and is an aggressive form of breast cancer (grows rapidly and tends to metastasize) frequently found in women under the age of 50. Due to resistance to most common breast cancer treatments, battling TNBC has proven difficult. About 30% of TNBCs will recur within the first three years after initial diagnosis and 5-year survival rates are drastically lower (77%) than other types of breast cancer (93%). We propose a strategy to test combination therapies on TNBCs in vitro and in vivo.
If successful, my work may not only pinpoint promising treatment strategies that can be used for future testing in clinical trials, but also identify genes that play a pivotal role in response/resistance to certain treatment options. These genes, in turn, may be used as diagnostic tools to identify patients that would most benefit from a specific type of treatment.

Ongoing projects
Main supervisor:

  • Peter Larsson

Co-supervisor:

  • Elisabeth Werner Rönnerman
  • Jenny Nyqvist
  • Slavica Janeva

Group members

  • Khalil Helou
  • Per Karlsson
  • Anikó Kovács
  • Eva Forssell-Aronsson
  • Peter Larsson
  • Elisabeth Werner Rönnerman
  • Jenny Nyqvist
  • Slavica Janeva

Financial support

  • Assar Gabrielsson Research Foundation for Clinical Cancer Research
  • Sahlgrenska University Hospital Research Foundation
  • Magnus Bergvall Research Foundation
  • Wilhelm and Martina Lundgren Research Foundation

Professional organizations

  • The European Association for Cancer Research (EACR)
  • Swedish Association of Scientists (Naturvetarna)
  • Swedish Association of Scientists at the University of Gothenburg (Naturvetarna vid GU)
  • Swedish Society of Medicine (Svenska Läkaresällskapet)
  • Radiation Research Society (RADRES)
  • American Association of Cancer Research (AACR)

Associate Editor

  • BMC Cancer

Popular science articles

  • Parris TZ. Bröstcancerpatientens tumör innehåller prognostisk information. Onkologi i Sverige 02-2014, 72-78.

ORCID
https://orcid.org/0000-0003-0834-5540

Latest publications

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) - Case Report
Slavica Janeva, Ulrika Hansson, Susanne Bram Ednersson, Balázs Márton, Khalil Helou et al.
Annals of Clinical and Medical Case Reports, Review article 2020
Review article

Design and creation of a wearable circular ultrasonic device for a soft screening and diagnosis of breast abnormalities
Amira Godih, Georges Nassar, Toshima Z Parris, Nadine Saad, Elie Helou et al.
J Cancer Sci Clin Ther, Journal article 2019
Journal article

Showing 41 - 50 of 128

2015

Biomarker gene discovery for radionuclide exposure and the impact of circadian variation and data convolution
Britta Langen, Nils Rudqvist, Toshima Z Parris, Johan Spetz, Khalil Helou et al.
Cancerfondens planeringsgrupp för onkologisk radionuklidterapi, Höstmöte, Linköping, Sweden, November 25-27, 2015, Conference contribution 2015
Conference contribution

Transcriptional effects of 177Lu-octreotate therapy on GOT1 tumor in nude mice using conventional and priming treatment schedules
Johan Spetz, Johanna Dalmo, Nils Rudqvist, Britta Langen, Toshima Z Parris et al.
15th International Congress of Radiation Research, Kyoto, Japan, May 25-29, Conference contribution 2015
Conference contribution

Gene expression signature in mouse thyroid tissue after 131I and 211At exposure
Eva Forssell-Aronsson, Nils Rudqvist, Johan Spetz, Emil Schüler, Britta Langen et al.
Cancerfondens riksplaneringsgrupp för onkologisk radionuklidterapi, Höstmöte, Linköping, Sweden, November 25-27, 2015 (invited), Conference contribution 2015
Conference contribution

Transcriptomic effects on GOT2 tumor in nude mice ̶ comparison between 177Lu-octreotate and external beam treatments
Johan Spetz, Britta Langen, Toshima Z Parris, Emil Schüler, John Swanpalmer et al.
Cancerfondens riksplaneringsgrupp för onkologisk radionuklidterapi. Vintermöte, Umeå, Sverige, Jan 22-23, Conference contribution 2015
Conference contribution

Hedgehog inhibitor Sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice
Johan Spetz, Nils Rudqvist, Britta Langen, Toshima Z Parris, Bo Wängberg et al.
Cancerfondens riksplaneringsgrupp för onkologisk radionuklidterapi, Höstmöte, Linköping, Sweden, November 25-27, 2015, Conference contribution 2015
Conference contribution

Proteomic analysis of normal mouse thyroids after 131I administration
Toshima Z Parris, Nils Rudqvist, Britta Langen, Johan Spetz, Emil Schüler et al.
15th International Congress of Radiation Research, Kyoto, Japan, May 25-29, Conference contribution 2015
Conference contribution

Showing 41 - 50 of 128

Page Manager: Katarina Olinder Eriksson|Last update: 3/28/2013
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?